What is it about?

Serotonin exerts a significant role in the mammalian central nervous system embryogenesis and brain ontogeny. Therefore, we investigate the effect of perinatal fluoxetine (FLX), a selective serotonin reuptake inhibitor, administration on the behavioral expression of adult male Swiss mice. For this purpose, two groups (n = 6 each, and ~ 35 g) of pregnant female Swiss mice were mated. Their offspring were treated with FLX (10 mg/Kg, s.c.) from postnatal day (PND) 5 to 15. At PND 16, one male puppy of each litter was euthanized, and the hippocampus was dissected for RNA analysis. At 70 days of life, the male offspring underwent a behavioral assessment in the open field, object recognition task, light-dark box, tail suspension and rotarod test

Featured Image

Why is it important?

the programmed animals had a decrease in TPH2, 5HT1a, SERT, BDNF, and LMX1B expression. Also, it was observed less time of immobility in tail suspension test and higher grooming time in the open field test. In the light-dark box test, the FLX-treated offspring had less time in the light side than control. We also observed a low cognitive performance in the object recognition task and poor motor skill learning in the rotarod test. These findings suggest that programming with FLX during the neonatal period alters a hippocampal serotonergic system, promoting anxiety and antidepressant behavior in adults, as well as a low mnemonic capacity

Perspectives

Overall, although many questions remain about the mechanisms through which perinatal SSRI treatment produces behavioral changes during adulthood, our results provide new information concerning a little more molecular mechanisms of the early-life SSRI exposure-induced affective disorders and cognitive impairment

Full Professor Ahmed R. G.
Division of Anatomy and Embryology, Zoology department, Faculty of Science, Beni-Suef University, Egypt.

Read the Original

This page is a summary of: Perinatal fluoxetine treatment promotes long-term behavioral changes in adult mice, Metabolic Brain Disease, August 2020, Springer Science + Business Media,
DOI: 10.1007/s11011-020-00606-2.
You can read the full text:

Read

Contributors

The following have contributed to this page